Boston continues its growth as the nation’s top biopharma cluster with the announcement by GenesisM that it had broken ground on its 154,000-sq-ft Class A biomanufacturing facility in nearby Bedford, MA. GenesisM is a joint venture between Bain Capital Real Estate and Botanic Properties.
The project marks a significant step forward in addressing the critical need for purpose-built life sciences manufacturing infrastructure in the Greater Boston region, according to Joshua Zinns, managing principal of Botanic Properties, adding that GenesisM’s proprietary enhanced core design provides a strong initial build-out that reduces tenant fit-out time and capital costs.
The facility, which is designed to support multiple tenants operating independently within regulated manufacturing suites, will feature 27-foot ceiling heights, up to 18 loading berths, 12,000 amps of power, and 40′ x 40′ column spacing. GenesisM’s enhanced core platform is designed to provide long-term operational flexibility, accelerate buildout timelines, and reduce upfront capital requirements for tenants, continued Zinns.
Construction is currently underway, with tenant fit-out commencing as early as Q2 2026 and final core and shell delivery expected in Q3 2026.
The post GenesisM Breaks Ground on its New Biomanufacturing Facility in the Greater Boston Area appeared first on GEN – Genetic Engineering and Biotechnology News.
